First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors

C. W. Menke, Carlos Gomez-Roca, Carla van Herpen, Andrew L. Coveler, Devalingam Mahalingam, Henk M. W. Verheul, Winette T. A. van der Graaf, Randolph Christen, Dominik Ruettinger, Stefan Weigand, Michael A. Cannarile, Florian Heil, Michael Brewster, Antje-Christine Walz, Tapan K. Nayak, Ernesto Guarin, Valerie Meresse, Christophe Le Tourneau

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)80046-80058
Issue number48
Publication statusPublished - 29 Nov 2016

Cite this